Association of intranasal esketamine, a novel ‘standard of care’ treatment and outcomes in the management of patients with treatment-resistant depression: protocol of a prospective cohort observational study of naturalistic clinical practice

INTRODUCTION: Esketamine is the S-enantiomer of racemic ketamine and has been approved by the Food and Drug Administration for the management of treatment resistant depression, demonstrating effective and long-lasting benefits. The objective of this observational study is to elucidate the associatio...

Descripción completa

Detalles Bibliográficos
Autores principales: Vazquez, Gustavo, Gutierrez, Gilmar, Rosenblat, Joshua, Schaffer, Ayal, Swainson, Jennifer, Karthikeyan, Ganapathy, Ravindran, Nisha, Lam, Raymond W, Do, André, Giacobbe, Peter, Hawken, Emily, Milev, Roumen
Formato: Online Artículo Texto
Lenguaje:English
Publicado: BMJ Publishing Group 2022
Materias:
Mental Health
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9438206/
https://www.ncbi.nlm.nih.gov/pubmed/36581972
http://dx.doi.org/10.1136/bmjopen-2022-060967

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9438206/
https://www.ncbi.nlm.nih.gov/pubmed/36581972
http://dx.doi.org/10.1136/bmjopen-2022-060967

Ejemplares similares